Topical Potassium Channel Blockage Improves Pharyngeal Collapsibility

Osman, A. Arnold; Mukherjee, Sutapa; Altree, Thomas J; Delbeck, Martina; Gehring, Doris; Hahn, Michael G.; Lang, Tina; Xing, Charles; Müller, Thomas; Weimann, G; Eckert, Danny J.

doi:10.1016/j.chest.2022.11.024

Cited by 13 publications

(5 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adrenergic α 1 antagonism decreases upper airway muscle activity during sleep (Taranto-Montemurro et al, 2021). Blockers of the tandem of pore domains in a weak inward rectifying K + channel (TWIK)-related acid-sensitive potassium channels, administered topically via intranasal spray reduces airway collapsibility in people with OSA (Osman et al, 2023).…”

Section: Inadequate Upper Airway Muscle Responsiveness During Sleepmentioning

confidence: 99%

“…Non‐anatomical causes of OSA include a low arousal threshold, high loop gain, and inadequate muscle response during sleep (Figure 1) (Eckert, 2018). While most current treatments for OSA target the upper airway crowding, non‐anatomical OSA endotypes represent novel targets for emerging pharmaceutical research (Altree & Eckert, 2022; Baillieul et al, 2022; Lim et al, 2021; Osman et al, 2023) (Figure 1). As previously described, quetiapine modulates multiple receptor subtypes with variable antagonist or agonist actions.…”

Section: How Might Quetiapine Affect Osa Severity Based On Its Pharma...mentioning

confidence: 99%

“…Adrenergic α 1 antagonism decreases upper airway muscle activity during sleep (Taranto‐Montemurro et al, 2021). Blockers of the tandem of pore domains in a weak inward rectifying K + channel (TWIK)‐related acid‐sensitive potassium channels, administered topically via intranasal spray reduces airway collapsibility in people with OSA (Osman et al, 2023). While quetiapine blocks voltage‐gated hERG potassium channels, even at low doses (100 mg), there are no data on how it affects tandem pore domain potassium channels (Kim et al, 2016; Lee, Choi et al, 2018).…”

Section: How Might Quetiapine Affect Osa Severity Based On Its Pharma...mentioning

confidence: 99%

See 2 more Smart Citations

Effects of the antipsychotic quetiapine on sleep and breathing: a review of clinical findings and potential mechanisms

Fauska,

Bastiampillai,

Adams

et al. 2023

Journal of Sleep Research

Self Cite

View full text Add to dashboard Cite

SummaryQuetiapine is an antipsychotic medication indicated for schizophrenia and bipolar disorder. However, quetiapine also has hypnotic properties and as such is increasingly being prescribed at low doses ‘off‐label’ in people with insomnia symptoms. Pharmacologically, in addition to its dopaminergic properties, quetiapine also modulates multiple other transmitter systems involved in sleep/wake modulation and potentially breathing. However, very little is known about the impact of quetiapine on obstructive sleep apnoea (OSA), OSA endotypes including chemosensitivity, and control of breathing. Given that many people with insomnia also have undiagnosed OSA, it is important to understand the effects of quetiapine on OSA and its mechanisms. Accordingly, this concise review covers the existing knowledge on the effects of quetiapine on sleep and breathing. Further, we highlight the pharmacodynamics of quetiapine and its potential to alter key OSA endotypes to provide potential mechanistic insight. Finally, an agenda for future research priorities is proposed to fill the current key knowledge gaps.

show abstract

Section: Inadequate Upper Airway Muscle Responsiveness During Sleepmentioning

confidence: 99%

Section: How Might Quetiapine Affect Osa Severity Based On Its Pharma...mentioning

confidence: 99%

Section: How Might Quetiapine Affect Osa Severity Based On Its Pharma...mentioning

confidence: 99%

See 1 more Smart Citation

Effects of the antipsychotic quetiapine on sleep and breathing: a review of clinical findings and potential mechanisms

Fauska,

Bastiampillai,

Adams

et al. 2023

Journal of Sleep Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…A randomised, placebo-controlled, double-blind crossover trial showed that a combination of noradrenergic and antimuscarinic agents (atomoxetine+oxybutynin) administered orally before bedtime on 1 night greatly reduced OSA severity [ 17 ]. A translational, placebo-controlled trial found that topical potassium channel antagonist improves pharyngeal collapsibility [ 41 ]. A stepwise approach to add-on and endotype-informed targeted combination therapy may control OSA in incomplete mandibular advancement splint responders [ 37 ].…”

Section: Hot Topics: Precision Medicine In Osamentioning

confidence: 99%

ERS International Congress 2023: highlights from the Sleep Disordered Breathing Assembly

Siciliano,

Bradicich,

Tondo

et al. 2023

ERJ Open Res

View full text Add to dashboard Cite

The topic of sleep-related breathing disorders is always evolving, and during the European Respiratory Society (ERS) International Congress 2023 in Milano (Italy), the latest research and clinical topics in respiratory medicine have been presented. The most interesting issues ranged from new diagnostic tools, including cardiovascular parameters and artificial intelligence, pathophysiological traits of SDB from routine polysomnography or polygraphy signals, up to new biomarkers and the diagnostic approach in patients with excessive daytime sleepiness. This article summarises the most relevant studies and topics to this extent presented at the ERS International Congress 2023. Each section has been written by Early Career Members of the ERS Assembly 4.

show abstract

“…[ 8–12 ] and translational clinical proof of concept findings e.g. [ 2 , 5 , 6 , 13–18 ] show considerable promise for the development of OSA pharmacotherapy.…”

mentioning

confidence: 99%